Should I buy or sell Clearside Biomedical stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLSD shares. View CLSD analyst ratings or view top-rated stocks .

What is Clearside Biomedical's stock price target for 2024?

4 brokerages have issued 1-year price objectives for Clearside Biomedical's stock. Their CLSD share price targets range from $4.00 to $6.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 358.7% from the stock's current price. View analysts price targets for CLSD or view top-rated stocks among Wall Street analysts .

How have CLSD shares performed in 2023?

Clearside Biomedical's stock was trading at $1.12 on January 1st, 2023. Since then, CLSD stock has decreased by 2.7% and is now trading at $1.09. View the best growth stocks for 2023 here .

When is Clearside Biomedical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our CLSD earnings forecast .

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical, Inc. (NASDAQ:CLSD) issued its quarterly earnings results on Monday, November, 13th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.01. The company had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.22 million. Clearside Biomedical had a negative trailing twelve-month return on equity of 533.87% and a negative net margin of 1,687.74%. During the same quarter in the prior year, the business earned ($0.13) EPS.

What other stocks do shareholders of Clearside Biomedical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO) , Ocular Therapeutix (OCUL) , Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , Melinta Therapeutics (MLNT) , Organigram (OGI) , Zosano Pharma (ZSAN) , Sorrento Therapeutics (SRNE) , Miragen Therapeutics (MGEN) and Gran Tierra Energy (GTE) .

When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Who are Clearside Biomedical's major shareholders?

Clearside Biomedical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Carmignac Gestion (3.42%), Simplex Trading LLC (0.00%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bradford T Whitmore, Bradford T Whitmore , Charles A Deignan , Clay Thorp, George M Lasezkay , Nancy J Hutson, Richard T Burke and Thomas Ciulla . View institutional ownership trends .

How do I buy shares of Clearside Biomedical?

Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Clearside Biomedical Stock Price, News & Analysis (NASDAQ:CLSD)

$1.10

+0.07 (+6.80%)

(As of 02:33 PM ET)

Compare

Today's Range: $1.06
▼
$1.13
50-Day Range: $0.68
▼
$1.14
52-Week Range: $0.65
▼
$1.85

Volume: 149,375 shs
Average Volume: 154,325 shs
Market Capitalization: $68.65 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Clearside Biomedical MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 358.7% Upside
$5.00 Price Target
Short Interest: Healthy
0.57% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.93
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$65,245 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.56) to ($0.58) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

554th out of 951 stocks

Pharmaceutical Preparations Industry

264th out of 439 stocks

3.5

Analyst's Opinion

Consensus Rating
Clearside Biomedical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Clearside Biomedical has a forecasted upside of 358.7% from its current price of $1.09.
Amount of Analyst Coverage
Clearside Biomedical has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.57% of the float of Clearside Biomedical has been sold short.
Short Interest Ratio / Days to Cover
Clearside Biomedical has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Clearside Biomedical has recently increased by 0.79%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Clearside Biomedical does not currently pay a dividend.
Dividend Growth
Clearside Biomedical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CLSD.

3.3

News and Social Media Coverage

News Sentiment
Clearside Biomedical has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Clearside Biomedical this week, compared to 1 article on an average week.
Search Interest
8 people have searched for CLSD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Clearside Biomedical to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Clearside Biomedical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $65,245.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 9.80% of the stock of Clearside Biomedical is held by insiders.
Percentage Held by Institutions
Only 13.70% of the stock of Clearside Biomedical is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Clearside Biomedical are expected to decrease in the coming year, from ($0.56) to ($0.58) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Clearside Biomedical is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Clearside Biomedical is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Clearside Biomedical has a P/B Ratio of 6.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Clearside Biomedical Stock (NASDAQ:CLSD)

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

CLSD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CLSD Stock News Headlines

December 1, 2023 | americanbankingnews.com

Clearside Biomedical (NASDAQ:CLSD) Coverage Initiated by Analysts at StockNews.com

November 23, 2023 | finanznachrichten.de

Clearside Biomedical, Inc.: Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

December 4, 2023 | Edge On The Street (Ad)

Is This The Most Overlooked Gold Investment Strategy of 2024?

There is little debate on the potential of gold in the next year and decade. The real issue becomes - what's the best gold investment strategy today? Some investors are opting for a unique "royalty" alternative that outshines other options like holding gold bullion or investing in volatile mining stocks.

November 15, 2023 | markets.businessinsider.com

Clearside Biomedical Earns Buy Rating Amid Successful Clinical Trials and Promising Partnerships: An Analysis by Jonathan Wolleben

November 14, 2023 | markets.businessinsider.com

Promising Developments and Financial Stability Bolster Buy Rating for Clearside Biomedical

November 14, 2023 | finance.yahoo.com

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call Transcript

November 13, 2023 | benzinga.com

Clearside Biomedical: Q3 Earnings Insights

November 13, 2023 | finance.yahoo.com

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

December 4, 2023 | Edge On The Street (Ad)

Is This The Most Overlooked Gold Investment Strategy of 2024?

November 13, 2023 | finance.yahoo.com

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

November 12, 2023 | msn.com

Clearside Biomedical Q3 2023 Earnings Preview

November 8, 2023 | finance.yahoo.com

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference

November 7, 2023 | finance.yahoo.com

Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting

November 6, 2023 | markets.businessinsider.com

Clearside Biomedical Receives Buy Rating Based on Promising Developments and Potential Market Opportunities

November 6, 2023 | morningstar.com

Clearside Biomedical Inc CLSD

November 3, 2023 | benzinga.com

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector®

November 3, 2023 | finance.yahoo.com

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®

November 2, 2023 | finance.yahoo.com

Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting

November 1, 2023 | finance.yahoo.com

Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD

October 31, 2023 | finance.yahoo.com

Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023

October 16, 2023 | finance.yahoo.com

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

October 4, 2023 | finance.yahoo.com

Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China

September 19, 2023 | finance.yahoo.com

Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference

September 14, 2023 | benzinga.com

Chief Financial Officer at Clearside Biomedical Exercises Options Worth $29K

August 19, 2023 | finanznachrichten.de

Clearside Biomedical, Inc.: Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

August 15, 2023 | markets.businessinsider.com

JMP Securities Sticks to Its Buy Rating for Clearside Biomedical (CLSD)

August 14, 2023 | finance.yahoo.com

Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

See More Headlines

Receive CLSD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/14/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CLSD
CUSIP: N/A
CIK: 1539029
Web: www.clearsidebio.com
Phone: (678) 270-3631
Fax: 678-270-4033
Employees: 36
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $6.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +358.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.61)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-32,950,000.00
Net Margins: -1,687.74%
Pretax Margin: -1,687.74%
Return on Equity: -533.87%
Return on Assets: -88.01%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.28
Quick Ratio: 5.28

Sales & Book Value

Annual Sales: $1.33 million
Price / Sales: 51.15
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.18 per share
Price / Book: 6.06

Miscellaneous

Outstanding Shares: 62,410,000
Free Float: 56,293,000
Market Cap: $68.03 million
Optionable: Optionable
Beta: 2.30

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. George M. Lasezkay J.D. (Age 71)
Pharm.D., Pharma.D., President, CEO & Director
Comp: $816.4k
Mr. Charles A. Deignan (Age 59)
Chief Financial Officer
Comp: $536.95k
Dr. Thomas A. Ciulla M.B.A. (Age 59)
M.D., Chief Medical Advisor-Retina
Comp: $597.21k
Ms. Jenny R. Kobin (Age 56)
Head of Investor Relations
Mr. Rick McElheny
Vice President of Corporate Development
Mr. Rafael V. Andino (Age 58)
Senior Vice President of Engineering & Manufacturing
Ms. Susan L. Coultas Ph.D.
Chief Clinical Officer
Mr. Leslie B. Zacks (Age 54)
Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CLSD Stock Analysis - Frequently Asked Questions

Should I buy or sell Clearside Biomedical stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLSD shares.
View CLSD analyst ratings or view top-rated stocks.
What is Clearside Biomedical's stock price target for 2024?: 4 brokerages have issued 1-year price objectives for Clearside Biomedical's stock. Their CLSD share price targets range from $4.00 to $6.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 358.7% from the stock's current price.
View analysts price targets for CLSD or view top-rated stocks among Wall Street analysts.
How have CLSD shares performed in 2023?: Clearside Biomedical's stock was trading at $1.12 on January 1st, 2023. Since then, CLSD stock has decreased by 2.7% and is now trading at $1.09.
View the best growth stocks for 2023 here.
When is Clearside Biomedical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our CLSD earnings forecast.
How were Clearside Biomedical's earnings last quarter?: Clearside Biomedical, Inc. (NASDAQ:CLSD) issued its quarterly earnings results on Monday, November, 13th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.01. The company had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.22 million. Clearside Biomedical had a negative trailing twelve-month return on equity of 533.87% and a negative net margin of 1,687.74%. During the same quarter in the prior year, the business earned ($0.13) EPS.

What other stocks do shareholders of Clearside Biomedical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Melinta Therapeutics (MLNT), Organigram (OGI), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Miragen Therapeutics (MGEN) and Gran Tierra Energy (GTE).
When did Clearside Biomedical IPO?: (CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.
Who are Clearside Biomedical's major shareholders?: Clearside Biomedical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Carmignac Gestion (3.42%), Simplex Trading LLC (0.00%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, Nancy J Hutson, Richard T Burke and Thomas Ciulla.
View institutional ownership trends.
How do I buy shares of Clearside Biomedical?: Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CLSD) was last updated on 12/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial